Journal Mobile Options
Table of Contents
Vol. 39, No. 2, 1998
Issue release date: February 1998
Eur Neurol 1998;39:111–118
(DOI:10.1159/000007917)

Cerebrospinal Fluid Levels of Amyloid Precursor Protein and Amyloid β-Peptide in Alzheimer’s Disease and Major Depression – Inverse Correlation with Dementia Severity

Hock C. · Golombowski S. · Müller-Spahn F. · Naser W. · Beyreuther K. · Mönning U. · Schenk D. · Vigo-Pelfrey C. · Bush A.M. · Moir R. · Tanzi R. · Growdon J.H. · Nitsch R.M.
a Department of Psychiatry, University of Basel, Switzerland; b Center for Molecular Biology, University of Heidelberg, c Research Laboratory, Boehringer Mannheim, Tutzing, d Center for Molecular Neurobiology, University of Hamburg, Germany; e Athena Neurosciences, South San Francisco, Calif., f Laboratory of Genetics and Aging, Massachusetts General Hospital East, Charlestown, Mass., and g Department of Neurology, Massachusetts General Hospital, Boston, Mass., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Alzheimer’s disease (AD) is the most common neurodegenerative disorder characterized by progressive dementia that ultimately leads to death. Histopathological hallmarks of AD include brain amyloid deposits and neurofibrillary tangles. Major depression is a frequent diagnosis in every gerontopsychiatric clinic that sees patients with both cognitive and affective disorders. Many depressed patients, in fact, are clinically characterized by cognitive impairments. Thus, an assay that excludes – or confirms – probable AD in cognitively impaired patients is desirable. Such assays may use protein markers that are derived from such histopathologically relevant molecules as the amyloid precursor protein (APP) and its derivatives including the amyloid β-peptides (Aβ). To evaluate the differential diagnostic properties of cerebrospinal fluid (CSF) Aβ and secreted soluble ectodomain (APPs), we quantitated CSF levels of these measures in AD patients and compared them to age-matched control patients with major depression. CSF levels of APPs and Aβ were similar in patients with AD or major depression, and the apolipoprotein E genotype had no influence on CSF levels of Aβ in AD patients. Measurement of Aβ peptide using a novel zinc/copper capture ELISA that detects aggregated Aβ peptides as well demonstrated similar levels in AD and major depression. In AD patients, CSF levels of total Aβ (Aβ1–40 plus Aβ1–42) were inversely correlated with a functional measure of dementia severity (NOSGER), suggesting that CSF levels of Aβ decrease with advancing severity of AD. Thus, CSF levels of Aβ are not useful for the differentiation of AD from major depression. However, CSF levels of Aβ reflect the severity of dementia and may be useful as biological markers of the stage of the disease.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Selkoe DJ: Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer’s disease. Annu Rev Cell Biol 1994;30:373–403.

    External Resources

  2. Emery OV, Oxman TE: Update on the dementia spectrum of depression. Am J Psychiatry 1992;149:305–317.
  3. Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, Cai XD, McKay DM, Tintner R, Frangione B, Younkin SG: Production of the Alzheimer amyloid β-protein by normal proteolytic processing. Science 1992;258:126–129.
  4. Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk DB: Characterization of amyloid peptide from human cerebrospinal fluid. J Neurochem 1993;61:1965–1968.

    External Resources

  5. Palmert MR, Berman Podlinsny M, Witker DS, Oltersdorf T, Younkin LH, Selkoe DJ, Younkin SG: The beta amyloid protein precursor of Alzheimer’s disease has soluble derivatives found in human brain and cerebrospinal fluid. Proc Natl Acad Sci USA 1989;86:6338–6342.
  6. Palmert MR, Usiak M, Mayeux R, Raskind M, Tourtellotte WW, Younkin SG: Soluble derivates of the β amyloid protein precursor in cerebrospinal fluid: Alterations in normal aging and Alzheimer’s disease. Neurology 1990;40:1028–1034.
  7. Kitaguchi N, Tokushima Y, Oishi K, Takahashi Y, Shiojiri S, Nakamura S, Tanaka S, Kodaira R, Ito H: Determination of amyloid beta protein precursors harboring active form of proteinase inhibitor domains in cerebrospinal fluid of Alzheimer’s disease patients by trypsin-antibody sandwich ELISA. Biochem Biophys Res Commun 1990;166:1453–1459.

    External Resources

  8. Prior R, Mönning U, Schreiter-Gasser U, Weidemann U, Weidemann A, Blennow K, Gottfries CG, Masters CL, Beyreuther K: Quantitative changes in the amyloid βA4 precursor protein in Alzheimer cerebrospinal fluid. Neurosci Lett 1991;124:69–73.
  9. Henriksson T, Barbour RM, Braa S, Ward P, Freitz LC, Johnson-Wood K, Chung HD, Burke W, Reinikainen KJ, Riekkinen P, Schenk DB: Analysis and quantitation of the beta-amyloid precursor protein in the cerebrospinal fluid of Alzheimer’s disease patients with a monoclonal antibody-based immunoassay. J Neurochem 1991;56:1037–1042.
  10. Nostrand WE van, Wagner SL, Shankle RW, Farrow JS, Dick M, Rozemuller JM, Kuiper MA, Wolters EC, Zimmermann J, Cotman CS, Cunningham DD: Decreased levels of soluble amyloid β-protein precursor in cerebrospinal fluid of live Alzheimer’s disease patients. Proc Natl Acad Sci USA 1992;89:2551–2555.
  11. Pirttila T, Kim KS, Mehta PD, Frey H, Wisniewski HM: Soluble amyloid beta-protein in the cerebrospinal fluid from patients with Alzheimer’s disease, vascular dementia and controls. J Neurol Sci 1994;127:90–95.
  12. Nitsch RM, Rebeck GW, Deng M, Richardson UI, Tennis M, Schenk DB, Vigo-Pelfrey C, Lieberburg I, Wurtman RJ, Hyman BT, Growdon JH: Cerebrospinal fluid levels of amyloid β-protein in Alzheimer’s disease: Inverse correlation with severity of dementia and effect of apolipoprotein E genotype. Ann Neurol 1995;37:512–518.
  13. Southwick PC, Yamagata SK, Echols CL, Higson GJ, Neynaber SA, Parson RE, Munroe WA: Assessment of amyloid beta-protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer’s disease. J Neurochem 1996;66:259–265.
  14. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R, Olson D, Southwick P, Wolfert R, Munroe B, Lieberburg I, Schenk DB: Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Ann Neurol 1995;38:643–648.
  15. Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, Sandbrink R, Masters CL, Beyreuther K: Analysis of heterogenous βA4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 1996;271:22908–22914.
  16. McKhann G, Drachman D, Folstein M, Katzmann R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  17. Folstein MF, Folstein SE, McHugh PR: Mini Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 1975;12:189–198.
  18. Spiegel R, Brunner C, Ermini-Funfschilling D, Monsch A, Notter M, Puxty J, Tremmel L: A new behavioral assessment scale for geriatric out- and in-patients: The NOSGER (Nurses’ Observation Scale for Geriatric Patients). J Am Geriatr Soc 1991;39:339–347.
  19. Weidemann A, König G, Bunke D, Fischer P, Salbaum JM, Masters CM, Beyreuther K: Identification, biogenesis, and localization of precursors of Alzheimer’s disease A4 amyloid protein. Cell 1989;57:115–126.
  20. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH: Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinergic acetylcholine receptors. Science 1992;255:728–730.

    External Resources

  21. Wasco W, Gurubhagavatula S, Paradis MD, Romano DM, Sisodia SS, Hyman BT, Neve RL, Tanzi RE: Isolation and characterization of APLP2 encoding a homologue of the Alzheimer’s associated amyloid β-protein precursor. Nature Genet 1993;5:95–99.
  22. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, McCormack R, Wolfert R, Selkoe D, Lieberburg I, Schenk D: Isolation and quantification of soluble Alzheimer’s β-peptide from biological fluids. Nature 1992;359:325–327.
  23. Beyreuther K, Pollwein P, Multhaup G, Monning U, Konig G, Dyrks T, Schubert W, Masters CL: Regulation and expression of the Alzheimer’s β/A4 amyloid protein precursor in health, disease and Down’s syndrome. Ann NY Acad Sci 1993;695:91–102.
  24. Seubert P, Oltersdorf T, Lee MG, Barbour R, Blomquist C, Davis DL, Bryant K, Fritz LC, Galasko D, Thal LJ, Lieberburg I, Schenk DB: Secretion of β-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide. Nature 1993;361:260–263.
  25. Citron M, Oltersdorf T, Haass C, McConlogue, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ: Mutation of the beta-amyloid precursor protein in familial Alzheimer’s disease increases beta-protein production. Nature 1992;360:672–674.
  26. Cai XD, Golde TE, Younkin SG: Release of excess amyloid beta-protein from a mutant amyloid beta-protein precursor. Science 1993;259:514–516.
  27. Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L Jr, Eckman C, Golde TE, Younkin SG: An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP(717)) mutants. Science 1994;264:1336–1340.
  28. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S: Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature 1996;383:710–713.
  29. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang FS, Cole G: Correlative memory deficits, A-beta elevation, and amyloid plaques in transgenic mice. Science 1996;274:99–102.
  30. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levylahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi RE, Wasco W, Lannfelt L, Selkoe D, Younkin S: Secreted amyloid β-protein similar to that in senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nature Med 1996;2:864–870.
  31. Davies L, Wolska B, Hilbich C, Multhaup G, Martins K, Simms G, Beyreuther K, Masters CL: A4 amyloid protein deposition and the diagnosis of Alzheimer’s disease. Neurology 1988;38:1688–1693.
  32. Rumble B, Retallack R, Hilbich M, Simms G, Multhaup G, Martins R, Hockey A, Montgomery P, Beyreuther K, Masters CL: Amyloid A4 protein and its precursor in Down’s syndrome and Alzheimer’s disease. New Engl J Med 1989;320:1446–1452.

    External Resources

  33. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993;261:921–923.
  34. Saunders AM, Strittmatter WJ, Schmechel D, St. George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-McLachlan DR, Alberts MJ, Hulette C, Crain B, Goldgaber D, Roses AD: Association of apolipoprotein E allele 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 1993;43:1467–1472.
  35. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD: Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:9649–9653.
  36. Gomez-Isla T, West HL, Rebeck GW, Harr SD, Growdon JH, Locascio JJ, Perls TT, Lipsitz LA, Hyman BT: Clinical and pathological correlates of apolipoprotein E e4 in Alzheimer’s disease. Ann Neurol 1996;39:62–70.
  37. Blessed G, Tomlinson BE, Roth M: The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Brit J Psychiatry 1968;114:797–811.
  38. Weintraub S: The record of independent living: An informant-completed measure of activities of daily living and behavior in elderly patients with cognitive impairment. Am J Alzheimer Care 1986;1:35–39.
  39. Thal LJ, Grundmann M, Golden M: Alzheimer’s disease: A correlational analysis of the Blessed Information-Memory-Concentration Test and the Mini-Mental State Exam. Neurology 1986;36:262–264.

    External Resources



Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50